演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

当院における進行・再発子宮頸癌に対するbevacizumab併用療法の有効性と安全性の検討

演題番号 : P94-2

[筆頭演者]
演者)戸上 真一:1 
[共同演者]
河村 俊彦:1、福田 美香:1、簗詰 伸太郎:1、神尾 真樹:1、小林 裕明:1

1:鹿児島大学・産婦人科

 

Background
Progression ·or recurrent cervical cancer is very poor prognosis, long-term survival is severe even if systemic chemotherapy is used. Bevacizumab (BV) was found to significantly improve OS in the GOG 240 trial compared to chemotherapy alone group. However, since recurrent cervical cancer often carries out radiation therapy, BV administration at the time of recurrence should pay attention to the event of fistula and intestinal perforation. In this study, we investigated the effectiveness and safety of BV combination chemotherapy in our hospital.
Method
In our institute, the patients with stage IVB or recurrent cervical cancer have received TC + BV combination therapy (TC + BV followed by maintenance of BV) . We reviewed retrospectively the effectiveness and safety of 28 patients who underwent TC + BV at our hospital for 2 years from May 2016 to April 2018.
Result
The background of 28 patients was as follow; age: median 50 years old (28 - 71), PS: 0/1/2 = 22/5/1, histological type: squamous cell carcinoma / adenocarcinoma / adenosquamous carcinoma / neuroendocrine Tumor / poorly differentiated cancer = 16/6/2/3/1, Progression / recurrence: Stage IVB / recurrence = 10/18, Radiation treatment history: None / Yes = 16/12, 2 patients received Docetaxel because of Paclitaxel allergy. All patients had measurable lesions, and RECIST was CR / PR / SD / PD = 3/21/4/0 and the response rate was 85.7%. The adverse events peculiar to BV showed hypertension in 5 cases (G2 / G3 = 4/1) and proteinuria in 3 cases (G1 / G2 = 2/1). Twelve cases had history of pelvic irradiation, five of them had recurrence within the irradiation field, but until now fistulae and gastrointestinal perforation have not occurred.
Conclusion
Fortunately we have been able to perform TC + BV without fistula and perforation until now. At the time of presentation, we will add additional cases and future follow-up data to report effectiveness and safety.

キーワード

臓器別:子宮

手法別:分子標的治療

前へ戻る